Indevus Opted For Additional Sanctura QT Study Due To "Climate" At FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Due to "the current climate" at FDA regarding QT issues, Indevus decided to conduct an additional QT study for its incontinence agent Sanctura instead of fulfilling FDA’s requests for additional analyses of existing data, review documents show.